KR20170007854A - 면역 장애의 치료 - Google Patents

면역 장애의 치료 Download PDF

Info

Publication number
KR20170007854A
KR20170007854A KR1020177000032A KR20177000032A KR20170007854A KR 20170007854 A KR20170007854 A KR 20170007854A KR 1020177000032 A KR1020177000032 A KR 1020177000032A KR 20177000032 A KR20177000032 A KR 20177000032A KR 20170007854 A KR20170007854 A KR 20170007854A
Authority
KR
South Korea
Prior art keywords
cells
subject
cell
stem cells
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177000032A
Other languages
English (en)
Korean (ko)
Inventor
실비우 이테스쿠
폴 시몬스
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Priority to KR1020237007387A priority Critical patent/KR102704978B1/ko
Publication of KR20170007854A publication Critical patent/KR20170007854A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y10S514/825—
    • Y10S514/866—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020177000032A 2014-06-10 2015-06-01 면역 장애의 치료 Ceased KR20170007854A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237007387A KR102704978B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUAU2014902194 2014-06-10
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
AUAU2014902257 2014-06-13
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007387A Division KR102704978B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Publications (1)

Publication Number Publication Date
KR20170007854A true KR20170007854A (ko) 2017-01-20

Family

ID=53385603

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177000032A Ceased KR20170007854A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020257031878A Pending KR20250143870A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020247029823A Active KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020237007387A Active KR102704978B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257031878A Pending KR20250143870A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020247029823A Active KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020237007387A Active KR102704978B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Country Status (9)

Country Link
US (3) US10624930B2 (enExample)
EP (2) EP3154565B1 (enExample)
JP (5) JP6800757B2 (enExample)
KR (4) KR20170007854A (enExample)
CN (2) CN114129598A (enExample)
AU (2) AU2015273799B2 (enExample)
CA (1) CA2950804C (enExample)
SG (1) SG11201609993YA (enExample)
WO (1) WO2015189063A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
AU2012262675B2 (en) * 2011-06-03 2016-05-19 Mesoblast, Inc Methods of treating or preventing neurological diseases
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10624930B2 (en) 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
US11760975B2 (en) 2017-03-31 2023-09-19 Wisconsin Alumi Research Foundation Generation of therapeutic cells using extracellular components of target organs
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
US12233094B2 (en) 2017-11-29 2025-02-25 Spinalcyte, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
KR20250130613A (ko) * 2022-12-09 2025-09-02 메조블라스트 인터내셔널 에스에이알엘 세포 조성물을 이용한 염증 치료 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
AU2009316541B2 (en) * 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
JP5678360B2 (ja) * 2009-09-28 2015-03-04 株式会社ジーシー 間葉系幹細胞の培養方法
US20140017787A1 (en) * 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
SI2785359T1 (sl) * 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
SG11201607925SA (en) * 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
US10624930B2 (en) 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders

Also Published As

Publication number Publication date
JP7680493B2 (ja) 2025-05-20
US10624930B2 (en) 2020-04-21
CN106659743B (zh) 2022-03-01
SG11201609993YA (en) 2016-12-29
JP2025109787A (ja) 2025-07-25
US20250319134A1 (en) 2025-10-16
HK1231386A1 (en) 2017-12-22
US20200281984A1 (en) 2020-09-10
CN106659743A (zh) 2017-05-10
KR20250143870A (ko) 2025-10-02
EP3154565A1 (en) 2017-04-19
JP7279212B2 (ja) 2023-05-22
CA2950804C (en) 2023-08-22
US11406669B2 (en) 2022-08-09
KR102704978B1 (ko) 2024-09-09
CA2950804A1 (en) 2015-12-17
WO2015189063A1 (en) 2015-12-17
JP2021028337A (ja) 2021-02-25
US12257270B2 (en) 2025-03-25
CN114129598A (zh) 2022-03-04
US20170106023A1 (en) 2017-04-20
EP3154565B1 (en) 2023-05-03
AU2015273799A1 (en) 2016-12-15
JP2017526619A (ja) 2017-09-14
JP2023090901A (ja) 2023-06-29
AU2020244403A1 (en) 2020-10-29
AU2020244403B2 (en) 2024-03-07
JP2022040254A (ja) 2022-03-10
JP6800757B2 (ja) 2020-12-16
KR20240135079A (ko) 2024-09-10
JP7009594B2 (ja) 2022-02-10
US20230141347A1 (en) 2023-05-11
KR20230038590A (ko) 2023-03-20
EP4137146A1 (en) 2023-02-22
KR102865313B1 (ko) 2025-09-29
AU2015273799B2 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
JP7680493B2 (ja) 免疫疾患の治療
AU2022200640B2 (en) Improved stem cell composition
US12616722B2 (en) Treatment of immune disorders
HK40088295A (en) Treatment of immune disorders
HK1231386B (en) Treatment of immune disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200525

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220103

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220721

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220401

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200525

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221130

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221121

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220721

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220401

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220103

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200525

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230302

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20221130

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101000462

Request date: 20230302

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101000462; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230302

Effective date: 20240730

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240730

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230302

Decision date: 20240730

Appeal identifier: 2023101000462